RecruitingNCT07091526

Whether Control of Serum Uric Acid (SUA) Improves Survival After Pancreatic Cancer

Whether Controlling Serum Uric Acid (SUA) Can Benefit Postoperative Survival in Patients With Pancreatic Cancer


Sponsor

Hepatopancreatobiliary Surgery Institute of Gansu Province

Enrollment

168 participants

Start Date

Jul 29, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

This retrospective study aims to analyze the impact of postoperative changes in serum uric acid (SUA) levels on the prognosis of patients undergoing pancreatic cancer resection.


Eligibility

Min Age: 18 YearsMax Age: 85 Years

Plain Language Summary

Simplified for easier understanding

This study investigates whether controlling uric acid levels in the blood improves survival for patients who have undergone surgery to remove pancreatic cancer. High uric acid has been linked to worse outcomes in some cancers, and this study aims to determine if reducing it helps. **You may be eligible if...** - You have a confirmed diagnosis of pancreatic cancer (primary) - You underwent radical surgery to remove your pancreatic cancer (e.g., Whipple procedure or distal pancreatectomy) - You survived at least 6 weeks after surgery **You may NOT be eligible if...** - You did not have surgery, or only had palliative or biopsy procedures - You required emergency dialysis after surgery - Your post-operative data is incomplete or unavailable Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTserum uric acid test

Detect the serum uric acid in blood sample


Locations(1)

Hepatopancreatobiliary Surgery Institute of Gansu Province

Lanzhou, Gansu, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07091526